(Q35553775)

English

Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit

scientific article published on February 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

Sidiropoulos P

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Bertsias G

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Kritikos HD

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Kouroumali H

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Voudouris K

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Boumpas DT

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

0 references

publication date

1 February 2004

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

144-148

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

27 July 2018

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

27 July 2018

Clinical outcome measures in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

27 July 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

27 July 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

27 July 2018

Limitations of randomized controlled clinical trials to depict accurately long-term outcomes in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

27 July 2018

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

27 July 2018

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

27 July 2018

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

26 September 2018

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

26 September 2018

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

26 September 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

26 September 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754877

15 November 2018

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/14722202

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice?

1 reference

https://pubmed.ncbi.nlm.nih.gov/14722202

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/14722202

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/14722202

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/14722202

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/14722202

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://pubmed.ncbi.nlm.nih.gov/14722202

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ARD.2003.015933

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35553775&oldid=1525284421"